Evaluation of meropenem regimens suppressing emergence of resistance in acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6773-6781

  Li, Xin ^a,b   Wang, Lin ^a   Zhang, Xian Jia ^a   Yang, Yang ^b   Gong, Wei Tao ^a   Xu, Bin ^a   Zhu, Ying Qun ^a   Liu, Wei ^a  

^a Third Hospital of Changsha   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MEZLOCILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CARBAPENEM SUSCEPTIBLE MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; ELIMINATION HALF-LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLLOW FIBER INFECTION MODEL; HUMAN; IN VITRO STUDY; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ACINETOBACTER INFECTIONS; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 84920755271     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03505-14     Document Type: Article

References (41)

1. Bergogne-Berezin E, Towner KJ. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165
2. Consales G, Gramigni E, Zamidei L, Bettocchi D, De Gaudio AR. 2011. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J. Crit. Care 26:453-459. http://dx.doi.org/10.1016/j.jcrc.2010.12.016
3. Villegas MV, Hartstein AI. 2003. Acinetobacter outbreaks, 1977-2000. Infect. Control Hosp. Epidemiol. 24:284-295. http://dx.doi.org/10.1086/502205
4. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to gramnegative bacteria. N. Engl. J. Med. 362:1804-1813. http://dx.doi.org/10 .1056/NEJMra0904124
5. Brigante G, Migliavacca R, Bramati S, Motta E, Nucleo E, Manenti M, Migliorino G, Pagani L, Luzzaro F, Vigano FE. 2012. Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. J. Med. Microbiol. 61:653-661. http://dx.doi.org/10.1099/jmm.0.040980-0
6. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol. 38:4086-4095
7. Landman D, Babu E, Shah N, Kelly P, Olawole O, Backer M, Bratu S, Quale J. 2012. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J. Antimicrob. Chemother. 67:1427-1431. http://dx.doi.org/10.1093/jac/dks063
8. Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X. 2011. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacinresistant subpopulations of Staphylococcus aureus. Antimicrob. Agents Chemother. 55:2409-2412. http://dx.doi.org/10.1128/AAC.00975-10
9. Ba BB, Feghali H, Arpin C, Saux MC, Quentin C. 2004. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokineticpharmacodynamic model. Antimicrob. Agents Chemother. 48:946-953. http://dx.doi.org/10.1128/AAC.48.3.946-953.2004
10. Nunez ML, Martinez-Toldos MC, Bru M, Simarro E, Segovia M, Ruiz J. 1998. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter. Scand. J. Infect. Dis. 30:421-423. http://dx.doi.org/10.1080/00365549850160774
11. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A. 2013. Emergence of imipenemresistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob. Agents Chemother. 57:1488-1495. http://dx.doi.org/10 .1128/AAC.01823-12
12. Lee HY, Chang RC, Su LH, Liu SY, Wu SR, Chuang CH, Chen CL, Chiu CH. 2012. Wide spread of Tn2006 in an AbaR4-type resistance island among carbapenem-resistant Acinetobacter baumannii clinical isolates in Taiwan. Int. J. Antimicrob. Agents 40:163-167. http://dx.doi.org/10.1016/j.ijantimicag.2012.04.018
13. Lee HY, Chen CL, Wang SB, Su LH, Chen SH, Liu SY, Wu TL, Lin TY, Chiu CH. 2011. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications. Int. J. Antimicrob. Agents 37:302-308. http://dx.doi.org/10 .1016/j.ijantimicag.2010.12.015
14. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG. 2007. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med. 33: 1524-1532. http://dx.doi.org/10.1007/s00134-007-0683-2
15. Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, Leu HS, Chiang PC. 2010. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 5:e9947. http://dx.doi.org/10.1371/journal .pone.0009947
16. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927. http://dx.doi.org/10.1128/AAC.49.12.4920-4927.2005
17. Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL. 2010. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob. Agents Chemother. 54:2646-2654. http://dx.doi.org/10.1128/AAC.00065-10
18. CLSI. 2014. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI document M100-S24. CLSI, Wayne, PA
19. Zhao X, Drlica K. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565. http://dx.doi.org/10.1086/338571
20. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613. http://dx.doi.org/10 .1128/AAC.47.5.1604-1613.2003
21. Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL. 2012. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob. Agents Chemother. 56:1229-1239. http://dx.doi.org/10.1128/AAC.01109-10
22. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Jones RN, Drusano GL, Bertino JS, Jr. 2010. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn. Microbiol. Infect. Dis. 68:251-258. http://dx.doi.org/10.1016/j.diagmicrobio.2010.06.012
23. Leelarasamee A, Rongrungruang Y, Trakulsomboon S, Pongpech P, Thanawattanawanich P, Jithavech P. 2008. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem). J. Med. Assoc. Thai. 91:980-988
24. Blondeau JM. 2009. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet. Dermatol. 20:383-396. http://dx.doi.org/10.1111/j.1365-3164.2009.00856.x
25. Canton R, Morosini MI. 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol. Rev. 35:977-991. http://dx.doi.org/10.1111/j.1574-6976.2011.00295.x
26. Credito K, Kosowska-Shick K, Appelbaum PC. 2010. Mutant prevention concentrations of four carbapenems against Gram-negative rods. Antimicrob. Agents Chemother. 54:2692-2695. http://dx.doi.org/10.1128/AAC .00033-10
27. Drlica K, Zhao X, Blondeau JM, Hesje C. 2006. Low correlation between MIC and mutant prevention concentration. Antimicrob. Agents Chemother. 50:403-404. http://dx.doi.org/10.1128/AAC.50.1.403-404.2006
28. Marcusson LL, Olofsson SK, Komp Lindgren P, Cars O, Hughes D. 2005. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J. Antimicrob. Chemother. 55:938-943. http://dx.doi.org/10.1093/jac/dki136
29. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. 2011. Activities of colistin-and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11:109. http://dx.doi.org/10.1186/1471-2334-11-109
30. Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z, Chu Y, Hu Z, Huang X. 2010. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int. J. Antimicrob. Agents 35:227-234. http://dx.doi.org/10.1016/j .ijantimicag.2009.11.010
31. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. 2006. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J. Antimicrob. Chemother. 58:1185-1192. http://dx.doi.org/10.1093/jac/dkl387
32. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. 2005. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob. Agents Chemother. 49:1337-1339. http://dx.doi.org/10 .1128/AAC.49.4.1337-1339.2005
33. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. 2007. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn. Microbiol. Infect. Dis. 57:153-161. http://dx.doi.org/10.1016/j .diagmicrobio.2006.06.014
34. Linde HJ, Lehn N. 2004. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J. Antimicrob. Chemother. 53:252-257. http://dx.doi.org/10 .1093/jac/dkh036
35. Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, Dovzhenko SA, Kobrin MB, Zinner SH. 2013. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob. Agents Chemother. 57:4956-4962. http://dx.doi.org/10.1128/AAC.00578-13
36. Zhao X, Drlica K. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436. http://dx.doi.org/10.1093/jac/dkn229
37. Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Melou A. 2009. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model. Antimicrob. Agents Chemother. 53:4740-4748. http://dx.doi.org/10.1128/AAC.00608-09
38. Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X. 2006. The mutant selection window in rabbits infected with Staphylococcus aureus. J. Infect. Dis. 194:1601-1608. http://dx.doi.org/10.1086/508752
39. Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob. Agents Chemother. 52:1924-1928. http://dx.doi.org/10.1128/AAC.01371-07
40. Martinez MN, Papich MG, Drusano GL. 2012. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob. Agents Chemother. 56: 2795-2805. http://dx.doi.org/10.1128/AAC.05360-11
41. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810. http://dx.doi.org/10.1128/AAC.01190-09.